
JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE) ›› 2021, Vol. 41 ›› Issue (9): 1207-1214.doi: 10.3969/j.issn.1674-8115.2021.09.011
• Basic research • Previous Articles Next Articles
Bei-bei XUAN1(
), Sai-nan GONG2, Jia-li LIU2, Quan QUAN2, Yu MENG2, Xiao-ling MU1(
)
Received:2021-03-26
Online:2021-09-28
Published:2021-08-24
Contact:
Xiao-ling MU
E-mail:xuanbeibei0806@163.com;mxl@hospital.cqmu.edu.cn
Supported by:CLC Number:
Bei-bei XUAN, Sai-nan GONG, Jia-li LIU, Quan QUAN, Yu MENG, Xiao-ling MU. Expression and clinical significance of DNA polymerase θ in endometrial cancer[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(9): 1207-1214.
Add to citation manager EndNote|Ris|BibTeX
URL: https://xuebao.shsmu.edu.cn/EN/10.3969/j.issn.1674-8115.2021.09.011
Fig 3 Relationship of the POLQ expression with age, grade and prognosis of the patients in the TCGA-UCECNote:A. Comparison of POLQ expression between different ages of patients. B. Comparison of POLQ expression among different grades of patients. C. Overall survival curves of the POLQ-high expression group and -low expression group. ①P=0.003, ②P=0.000.
| Group | Total/n | Expression of POLQ/n | ≥1 score/% | ≥5 score/% | |||
|---|---|---|---|---|---|---|---|
| - | + | ++ | +++ | ||||
| EC | 127 | 9 | 54 | 38 | 26 | 92.9 | 50.4 |
| Normal endometrium | 22 | 8 | 11 | 3 | 0 | 63.6 | 13.6 |
| P value | ‒ | ‒ | ‒ | ‒ | ‒ | 0.000 | 0.001 |
Tab 1 Expression of POLQ in the normal endometrium and EC tissues
| Group | Total/n | Expression of POLQ/n | ≥1 score/% | ≥5 score/% | |||
|---|---|---|---|---|---|---|---|
| - | + | ++ | +++ | ||||
| EC | 127 | 9 | 54 | 38 | 26 | 92.9 | 50.4 |
| Normal endometrium | 22 | 8 | 11 | 3 | 0 | 63.6 | 13.6 |
| P value | ‒ | ‒ | ‒ | ‒ | ‒ | 0.000 | 0.001 |
Fig 5 Immunohistochemical staining of POLQ in the paraffin sections of normal endometrium and EC tissues (×200)Note:A/B. Negative or weakly positive in normal endometrium. C/D. Strongly positive in EC.
| ≥5 score/n(%) | P value | |
|---|---|---|
| Age/year | 0.246 | |
| ≥60(n=50) | 22 (44.0) | |
| <60(n=77) | 42 (54.5) | |
| Type | 0.742 | |
| Ⅰ(n=89) | 44 (49.4) | |
| Ⅱ(n=38) | 20 (52.6) | |
| Stage | 0.038 | |
| Ⅰ(n=83) | 35 (42.2) | |
| Ⅱ(n=28) | 18 (64.3) | |
| Ⅲ(n=16) | 11 (68.8) | |
| Grade | 0.533 | |
| 1(n=23) | 14 (60.9) | |
| 2(n=72) | 35 (48.6) | |
| 3(n=32) | 15 (46.9) | |
| Myometrial invasion | 0.954 | |
| Superficial(n=89) | 45 (50.6) | |
| Deep(n=38) | 19 (50.0) | |
| Lymph node metastasis | 0.038 | |
| Negative(n=121) | 49 (40.5) | |
| Positive(n=6) | 5 (83.3) | |
| Tumor size/cm | 0.154 | |
| ≥2(n=90) | 49 (54.4) | |
| <2(n=37) | 15 (40.5) | |
| ER① | 0.478 | |
| Negative(n=19) | 11 (57.9) | |
| Positive(n=104) | 51 (49.0) | |
| PR① | 0.790 | |
| Negative(n=27) | 13 (48.1) | |
| Positive(n=96) | 49 (51.0) |
Tab 2 Expression of POLQ protein in the EC tissues of patients with different clinical characteristics
| ≥5 score/n(%) | P value | |
|---|---|---|
| Age/year | 0.246 | |
| ≥60(n=50) | 22 (44.0) | |
| <60(n=77) | 42 (54.5) | |
| Type | 0.742 | |
| Ⅰ(n=89) | 44 (49.4) | |
| Ⅱ(n=38) | 20 (52.6) | |
| Stage | 0.038 | |
| Ⅰ(n=83) | 35 (42.2) | |
| Ⅱ(n=28) | 18 (64.3) | |
| Ⅲ(n=16) | 11 (68.8) | |
| Grade | 0.533 | |
| 1(n=23) | 14 (60.9) | |
| 2(n=72) | 35 (48.6) | |
| 3(n=32) | 15 (46.9) | |
| Myometrial invasion | 0.954 | |
| Superficial(n=89) | 45 (50.6) | |
| Deep(n=38) | 19 (50.0) | |
| Lymph node metastasis | 0.038 | |
| Negative(n=121) | 49 (40.5) | |
| Positive(n=6) | 5 (83.3) | |
| Tumor size/cm | 0.154 | |
| ≥2(n=90) | 49 (54.4) | |
| <2(n=37) | 15 (40.5) | |
| ER① | 0.478 | |
| Negative(n=19) | 11 (57.9) | |
| Positive(n=104) | 51 (49.0) | |
| PR① | 0.790 | |
| Negative(n=27) | 13 (48.1) | |
| Positive(n=96) | 49 (51.0) |
Fig 6 Comparison of POLQ expression in the patients with different stages and lymph node metastasis conditionsNote:A. Expression of POLQ in different stages of EC tissues. B. Expression of POLQ in the patients with and without lymph node metastasis. ①P=0.008, ②P=0.023.
| Age/year | ‒ | ‒ | ‒ | |
| <60 | ‒ | ‒ | ‒ | |
| ≥60 | ‒ | ‒ | ‒ | |
| Stage | ‒ | ‒ | ‒ | |
| Ⅰ‒Ⅱ | ‒ | ‒ | ‒ | |
| Ⅲ | ‒ | ‒ | ‒ | |
| Grade | ‒ | ‒ | ‒ | |
| 1‒2 | ‒ | ‒ | ‒ | |
| 3 | ‒ | ‒ | ‒ | |
| POLQ score/score | ‒ | ‒ | ||
| 0‒4 | ‒ | ‒ | ||
| 5‒12 | ‒ | ‒ | ||
Tab 3 Multivariate Cox analysis of DFS and OS in the EC patients
| Age/year | ‒ | ‒ | ‒ | |
| <60 | ‒ | ‒ | ‒ | |
| ≥60 | ‒ | ‒ | ‒ | |
| Stage | ‒ | ‒ | ‒ | |
| Ⅰ‒Ⅱ | ‒ | ‒ | ‒ | |
| Ⅲ | ‒ | ‒ | ‒ | |
| Grade | ‒ | ‒ | ‒ | |
| 1‒2 | ‒ | ‒ | ‒ | |
| 3 | ‒ | ‒ | ‒ | |
| POLQ score/score | ‒ | ‒ | ||
| 0‒4 | ‒ | ‒ | ||
| 5‒12 | ‒ | ‒ | ||
| 1 | Lewin SN. Revised FIGO staging system for endometrial cancer[J]. Clin Obstet Gynecol, 2011, 54(2): 215-218. |
| 2 | Lortet-Tieulent J, Ferlay J, Bray F, et al. International patterns and trends in endometrial cancer incidence, 1978‒2013[J]. J Natl Cancer Inst, 2018, 110(4): 354-361. |
| 3 | 魏丽惠. 重视子宫内膜癌的筛查[J]. 中华妇产科杂志, 2013, 48(12): 881-883. |
| 4 | Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma[J]. Lancet Oncol, 2012, 13(8): e353-e361. |
| 5 | Morice P, Leary A, Creutzberg C, et al. Endometrial cancer[J]. Lancet, 2016, 387(10023): 1094-1108. |
| 6 | Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1): 5-29. |
| 7 | Ashour ME, Mosammaparast N. Mechanisms of damage tolerance and repair during DNA replication[J]. Nucleic Acids Res, 2021, 49(6): 3033-3047. |
| 8 | Ranjha L, Howard SM, Cejka P. Main steps in DNA double-strand break repair: an introduction to homologous recombination and related processes[J]. Chromosoma, 2018, 127(2): 187-214. |
| 9 | Chang HHY, Pannunzio NR, Adachi N, et al. Non-homologous DNA end joining and alternative pathways to double-strand break repair[J]. Nat Rev Mol Cell Biol, 2017, 18(8): 495-506. |
| 10 | Koole W, van Schendel R, Karambelas AE, et al. A polymerase theta-dependent repair pathway suppresses extensive genomic instability at endogenous G4 DNA sites[J]. Nat Commun, 2014, 5: 3216. |
| 11 | Yousefzadeh MJ, Wyatt DW, Takata K, et al. Mechanism of suppression of chromosomal instability by DNA polymerase POLQ[J]. PLoS Genet, 2014, 10(10): e1004654. |
| 12 | Kamp JA, van Schendel R, Dilweg IW, et al. BRCA1-associated structural variations are a consequence of polymerase theta-mediated end-joining[J]. Nat Commun, 2020, 11(1): 3615. |
| 13 | Lemée F, Bergoglio V, Fernandez-Vidal A, et al. DNA polymerase theta up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability[J]. Proc Natl Acad Sci U S A, 2010, 107(30): 13390-13395. |
| 14 | 李学孝, 吴爱国, 胡斌, 等. DNA聚合酶θ对乳腺癌细胞株MCF-7放射敏感性的影响[J]. 中华实验外科杂志, 2012, 29(5): 801-804. |
| 15 | Shima N, Munroe RJ, Schimenti JC. The mouse genomic instability mutation chaos1 is an allele of Polq that exhibits genetic interaction with Atm[J]. Mol Cell Biol, 2004, 24(23): 10381-10389. |
| 16 | Seki M, Marini F, Wood RD. POLQ (Pol θ), a DNA polymerase and DNA-dependent ATPase in human cells[J]. Nucleic Acids Res, 2003, 31(21): 6117-6126. |
| 17 | Kawamura K, Bahar R, Seimiya M, et al. DNA polymerase θ is preferentially expressed in lymphoid tissues and upregulated in human cancers[J]. Int J Cancer, 2004, 109(1): 9-16. |
| 18 | Leoncini E, Ricciardi W, Cadoni G, et al. Adult height and head and neck cancer: a pooled analysis within the INHANCE Consortium[J]. Eur J Epidemiol, 2014, 29(1): 35-48. |
| 19 | Allera-Moreau C, Rouquette I, Lepage B, et al. DNA replication stress response involving PLK1, CDC6, POLQ, RAD51 and CLASPIN upregulation prognoses the outcome of early/mid-stage non-small cell lung cancer patients[J]. Oncogenesis, 2012, 1(10): e30. |
| 20 | Pillaire MJ, Selves J, Gordien K, et al. A 'DNA replication' signature of progression and negative outcome in colorectal cancer[J]. Oncogene, 2010, 29(6): 876-887. |
| 21 | Higgins GS, Harris AL, Prevo R, et al. Overexpression of POLQ confers a poor prognosis in early breast cancer patients[J]. Oncotarget, 2010, 1(3): 175-184. |
| 22 | Wood RD, Doublié S. DNA polymerase θ (POLQ), double-strand break repair, and cancer[J]. DNA Repair (Amst), 2016, 44: 22-32. |
| 23 | van Schendel R, van Heteren J, Welten R, et al. Genomic scars generated by polymerase θ reveal the versatile mechanism of alternative end-joining[J]. PLoS Genet, 2016, 12(10): e1006368. |
| 24 | Ahrabi S, Sarkar S, Pfister SX, et al. A role for human homologous recombination factors in suppressing microhomology-mediated end joining[J]. Nucleic Acids Res, 2016, 44(12): 5743-5757. |
| 25 | Goullet de Rugy T, Bashkurov M, Datti A, et al. Excess Polθ functions in response to replicative stress in homologous recombination-proficient cancer cells[J]. Biol Open, 2016, 5(10): 1485-1492. |
| 26 | Ceccaldi R, Liu JC, Amunugama R, et al. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair[J]. Nature, 2015, 518(7538): 258-262. |
| 27 | Nik-Zainal S, Davies H, Staaf J, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences[J]. Nature, 2016, 534(7605): 47-54. |
| 28 | Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer[J]. Nature, 2013, 500(7463): 415-421. |
| 29 | Carvajal-Garcia J, Cho JE, Carvajal-Garcia P, et al. Mechanistic basis for microhomology identification and genome scarring by polymerase θ[J]. Proc Natl Acad Sci U S A, 2020, 117(15): 8476-8485. |
| [1] | CHEN Siyuan, SHI Qing, FU Di, WANG Li, CHENG Shu, XU Pengpeng, ZHAO Weili. Clinicopathologic characteristics, gene mutation profile, and prognostic analysis of diffuse large B-cell lymphoma with lung involvement [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(9): 1214-1220. |
| [2] | YAN Zhi, WU Xingyue, YAO Weiqin, YAN Lingzhi, JIN Song, SHANG Jingjing, SHI Xiaolan, WU Depei, FU Chengcheng. Dynamic changes and prognostic significance of immunoparesis in newly diagnosed multiple myeloma patients [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(7): 807-814. |
| [3] | XU Tianyun, SHEN Yiming, JIANG Meng. Clinical management of heart failure with improved ejection fraction: treatment and maintenance [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(4): 493-499. |
| [4] | WANG Boen, CHEN Siyuan, SHI Qing, ZHANG Muchen, YI Hongmei, DONG Lei, WANG Li, CHENG Shu, XU Pengpeng, ZHAO Weili. Clinicopathologic characteristics of patients with kidney-involved diffuse large B-cell lymphoma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(9): 1162-1168. |
| [5] | WEI Yunxin, JIANG Xushun, CAI Mengyao, WEN Ruizhi, DU Xiaogang. Correlation analysis of COMP and autophagy in diabetic nephropathy and its functional verification [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(7): 847-858. |
| [6] | SONG Chenlu, XIANG Jun, YANG Huizhong. Early alarming effect of serum heparin-binding protein on prognosis and occurrence of sepsis in severely burned patients [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(4): 474-481. |
| [7] | WANG Xin, WANG Xiaoxia, LI Yanqing, ZHENG Yongxin, WU Jie, REN Meng, JIA Xiangdong, XU Tianxiang. Expression and clinical significance of geranylgeranyl diphosphate synthase1 (GGPS1) in lung squamous cell carcinoma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(3): 312-324. |
| [8] | WANG Guijie, DU Chuanchong, LU Ye, ZHAO Jian, SHEN Xie, JIN Donglin, GENG Jiacai. Changes of serum high mobility group box 1 and soluble triggering receptor expressed on myeloid cells-1 in patients with multiple injuries and their prognostic significance [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(3): 350-357. |
| [9] | DENG Qingsong, ZHANG Changqing, TAO Shicong. Exploration of the relationship between nicotinamide metabolism-related genes and osteoarthritis [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(2): 145-160. |
| [10] | YU Siwei, XU Ziqi, TAO Mengyu, FAN Guangjian. Mechanistic study on the promotion of pancreatic cancer progression through upregulation of ZNF143 by dysregulated fatty acid metabolism [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(10): 1255-1265. |
| [11] | LUO Mengxing, ZOU Xin, GAO Yaxian, WU Xiaocui, YU Fangyou, HU Yang, ZENG Qibing, LIU Zhonghua. Analysis of the effect of anti-tuberculosis treatment and lung injury in patients with tuberculosis combined with underlying disease [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(8): 1017-1023. |
| [12] | DU Shaoqian, TAO Mengyu, CAO Yuan, WANG Hongxia, HU Xiaoqu, FAN Guangjian, ZANG Lijuan. CXCL9 expression in breast cancer and its correlation with the characteristics of tumor immunoinfiltration [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(7): 860-872. |
| [13] | LI Qinglin, WANG Wenbo, LIU Wei. Bioinformatics analysis of pathological mechanism of degenerated tendon via stress deprivation [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(5): 560-570. |
| [14] | LI Ying, TAN Yangxia, YIN Hongxin, JIANG Yanling, CHEN Li, MENG Guoyu. Research progress in the pathogenesis and prognosis of ZNF384 fusion subtype acute leukemia [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(5): 631-640. |
| [15] | MEN Ru, ZHU Minxia, ZHANG Weiming. Serum potassium level in maintenance hemodialysis patients and its effect on outcome [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(4): 507-513. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||